Search by Drug Name or NDC
NDC 00006-5007-01 DELSTRIGO 100; 300; 300 mg/1; mg/1; mg/1 Details
DELSTRIGO 100; 300; 300 mg/1; mg/1; mg/1
DELSTRIGO is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE.
MedlinePlus Drug Summary
The combination of doravirine, lamivudine, and tenofovir is used to treat human immunodeficiency virus (HIV) infection in adults who have not been treated with other HIV medications. The combination is also used to replace current medication therapy in certain people already taking HIV medications. Doravirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Lamivudine and tenofovir are in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). The combination of doravirine, lamivudine, and tenofovir works by decreasing the amount of HIV in the body. Although the combination of doravirine, lamivudine, and tenofovir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 00006-5007-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Doravirine, Lamivudine, and Tenofovir
Product Information
| NDC | 00006-5007 |
|---|---|
| Product ID | 0006-5007_159c05bc-4bee-42d5-90a8-70da539ed1b5 |
| Associated GPIs | 12109903270320 |
| GCN Sequence Number | 078822 |
| GCN Sequence Number Description | doravirine/lamivu/tenofov diso TABLET 100-300 MG ORAL |
| HIC3 | W5Q |
| HIC3 Description | ARTV NUCLEOSIDE,NUCLEOTIDE,NON-NUCLEOSIDE RTI COMB |
| GCN | 45217 |
| HICL Sequence Number | 045195 |
| HICL Sequence Number Description | DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE |
| Brand/Generic | Brand |
| Proprietary Name | DELSTRIGO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | doravirine, lamivudine, and tenofovir disoproxil fumarate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 100; 300; 300 |
| Active Ingredient Units | mg/1; mg/1; mg/1 |
| Substance Name | DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunod |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA210807 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00006-5007-01 (00006500701)
| NDC Package Code | 0006-5007-01 |
|---|---|
| Billing NDC | 00006500701 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (0006-5007-01) |
| Marketing Start Date | 2018-07-20 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 86.8211 |
| Pricing Unit | EA |
| Effective Date | 2024-01-06 |
| NDC Description | DELSTRIGO 100-300-300 MG TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |